ADLDpk.org
  • Home
  • About
    • ADLD Team
    • Fast Facts
    • History
    • A Word From Chairman
    • Area Of Operation
    • Aims And Objectives
    • Services offered
    • Mission
    • Plan of operation
    • Executive council
    • Midterm Progress Report
  • Forum
  • Education & Training
    • Practice Guidelines
    • Clinical Methods
    • CME
    • Drugs
  • Blog
  • Gallery
  • Contact
  • More >>
    • Membership
    • Books
    • Endorsements
    • Projects
    • Carrier Opportunities
    • Pedometer
    • Diabetes Risk Calculator
    • Android App

Autoimmune Hepatitis (AIH) ~ CME presentation (By Dr. Usman Javed)

3/11/2016

0 Comments

 
An inflammatory liver disease of unknown cause characterized by suppressor T-cell defects with autoantibodies directed against hepatocyte surface antigens. AIH predominantly affects young or middle-aged women (bimodal, i.e 10–30yrs or >40yrs old).

Presentation:

​Up to 40% present with acute hepatitis and signs of autoimmune disease such as fever, malaise, urticarial rash, polyarthritis. The remainder present with gradual jaundice or are asymptomatic and diagnosed incidentally with signs of chronic liver disease.

Pathogenesis:

Involves the combination of genetic predisposition and environmental triggers. 
Picture
Genetic predisposition
  • Genetic susceptibility to developing autoimmune hepatitis has been associated with the HLA haplotypes B8, B14, DR3, DR4, and Dw3
  • C4A gene deletions are associated with the development of autoimmune hepatitis
Environmental triggers include 
  • Viruses:
eg Rubella, Epstein-Barr, and hepatitis A, B, and C.
  • Drugs
eg Aspartame

​Investigations:

  • CBC (pancytopenia secondary to hyperspleenism)
  • Bilirubin, ALT, AST, ALP (usually all raised)
  • Autoantibodies
    • ANA
    • ASMA
    • Anti-LKM
    • Anti – SLA
  • Serum IGg Levels
  • Liver Biopsy
  • Investigations to rule out other causes of CLD
    • AntiHCV, HBsAg
Classification of autoimmune hepatitis is based on type of autoantibodies:  Type 1 positive ANA and ASMA (classic form, responds well to steroids) Type 2 positive LKM-1 (typically female children and teenagers; disease can be severe), LKM-2 or LKM-3;  Type 3 positive antibodies against soluble liver antigen(anti-SLA)  Type 4 No Autoantibodies detected (~20%)

​Liver Biopsy

“Piecemeal necrosis” or interface hepatitis with lobular or panacinar inflammation (lymphocytic and plasmacytic infiltration) are the histologic hallmarks of the disease.
It refers specifically to a loss and degeneration of (limiting plate) hepatocytes at the lobular-portal-interface, producing a moth-eaten irregular appearance.
  • In Autoimmune Hepatitis Bridging  or interface hepatitis occurs
Picture

How to Diagnose:

Picture

​Differential Diagnosis

AIH is a diagnosis of exclusion; Viral and drug-induced causes must be ruled out.
  • Primary Biliary Cirhosis
  • Primary Sclerosing Cholangitis
  • Chronic Viral Hepatitis
  • Overlap Syndrome
    • AIH plus PBC, AIH plus PSC
Picture

​Overlap Syndromes:

Picture

​Associated Conditions

  • Type I diabetes mellitus
  • Thyroiditis
  • Idiopathic thrombocytopenic purpura
  • Ulcerative colitis
  • Rheumatoid arthritis
  • Primary biliary cirrhosis and primary sclerosing cholangitis occasionally overlap with AIH

​Indications for treatment

Picture

Treatment

Immunosuppressant therapy
First Line Drugs:
  • Prednisolone
  • Azathioprine
Second Line Drugs:
  • Cyclosporine
  • Tacrolimus
  • Mycophenolate Mofetil

Liver transplantation
Prednisolone monotherapy and prednisolone in combination with Azathioprine are equally effective in induction and maintenance of remission
Picture
Combination therapy is preferred in:
  • Osteoporosis, Diabetes, HTN, Obesity, Acne, Depression
Prednisone alone preferred in
  • Cytopenias
  • Pregnancy

Second Line drugs are considered if there is no improvement in clinical, lab and histological features after 6 weeks of therapy

​Endpoints of treatment

Primary End Point
  • Normalization of ALT

Secondary End Point
  • Normalization of  Histologic activity

Final Goal
  • To achieve sustained remission without need of drug therapy or at lowest dose possible, and maintaining the hepatic reserve

Follow Up:

ALT and IgG level may be followed two weekly on a regular basis as a marker of disease responsiveness to therapy.

Reference:

​AASLD Guidelines
0 Comments

    Blog Authors:
    Dr. Saleem Qureshi
    Dr. Musarrat Iqbal
    Dr. Usman Javed

    Archives

    January 2022
    April 2021
    March 2021
    December 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    February 2019
    January 2019
    August 2017
    July 2017
    March 2017
    October 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015

    Categories

    All
    ADLD
    Camp Report
    Career
    CDLD
    Clinical Methods
    CME
    Devices
    Diabetes
    Dr Saleem Qureshi
    Dr Suddle
    Dr Usman Javed
    Endorsements
    Imran Abbas
    Insulin Pump
    Medicine
    Motivation
    News
    Photos
    Shoaib Suddle
    Videos
    Zeba Bakhtiar

    RSS Feed

    Picture
    Picture
    Picture
    Picture
    Picture
Powered by Create your own unique website with customizable templates.